Please ensure Javascript is enabled for purposes of website accessibility

Why Nightstar Therapeutics Stock Skyrocketed 71% in March

By Beth McKenna - Apr 3, 2019 at 7:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage gene therapy company got some love from biotech giant Biogen last month.

What happened

Shares of Nightstar Therapeutics (NITE), a U.K-based clinical-stage gene therapy company, soared 71.2% in March, according to data from S&P Global Market Intelligence

For some context, the S&P 500 index returned 1.9% last month.

Image of woman's eye on a screen facing a person, presumably a healthcare professional who is examining the woman's eyes/vision.

Image source: Getty Images.

So what

We can attribute Nightstar Therapeutics stock's stellar performance last month to a buyout offer from biotech giant Biogen (BIIB 0.26%). On March 4, the companies announced the $877 million deal that involves Biogen paying $25.50 in cash for each share of Nightstar, which represents a fat 68% premium to its share price at the close of the previous trading day. The deal is expected to close midyear. 

This big premium makes sense when one considers that "Nightstar's late-stage gene therapy NSR-REP1 for choroideremia (a rare, retinal disorder that has no available treatments) is expected to generate over $700 million in annual peak sales, if approved," according to my colleague George Budwell. 

NITE Total Return Price Chart

Data by YCharts.

While some of Nightstar's newer investors might have landed a windfall, those who bought the stock soon after the company's September 2017 initial public offering (IPO) will book only a small gain, as the chart below shows. The chart also illustrates how volatile shares of small biotechs can be.

NITE Total Return Price Chart

Data by YCharts.

Now what

There's nothing for Nightstar investors to do at this point. If the Biogen deal goes through, they'll collect $25.50 in cash for each share they own.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.93 (0.26%) $0.55
Nightstar Therapeutics Limited Stock Quote
Nightstar Therapeutics Limited
NITE

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.